We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...

The US FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) ...

The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved event-free survival in resectable gastric and gastroesophageal junction cancers. The ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by enabling precise monitoring of treatment responses. In this exclusive ...

A durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for the treatment of adults with resectable non-small cell lung cancer. The recommendation is based on ...